These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2623329)

  • 21. Randomized multicenter 2 x 2-factorial design study of chemo/endocrine therapy in operable, node-positive breast cancer (protocol 2).
    Scheurlen H
    Recent Results Cancer Res; 1989; 115():226-35. PubMed ID: 2696037
    [No Abstract]   [Full Text] [Related]  

  • 22. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
    Pritchard KI
    Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
    Tormey DC; Gray R; Gilchrist K; Grage T; Carbone PP; Wolter J; Woll JE; Cummings FJ
    Cancer; 1990 Jan; 65(2):200-6. PubMed ID: 2403834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
    Bianco AR; De Placido S; Gallo C; Pagliarulo C; Marinelli A; Petrella G; D'Istria M; Delrio G
    Lancet; 1988 Nov; 2(8620):1095-9. PubMed ID: 2903322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The place of chemotherapy in the treatment of early breast cancer.
    Buzdar A
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):16-20. PubMed ID: 9741784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
    Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
    J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant chemotherapy in postmenopausal women: results of sequential noncross-resistant regimens.
    Brambilla C; Rossi A; Valagussa P; Bonadonna G
    World J Surg; 1985 Oct; 9(5):728-37. PubMed ID: 3840630
    [No Abstract]   [Full Text] [Related]  

  • 28. Risk of menopause during the first year after breast cancer diagnosis.
    Goodwin PJ; Ennis M; Pritchard KI; Trudeau M; Hood N
    J Clin Oncol; 1999 Aug; 17(8):2365-70. PubMed ID: 10561298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoendocrine versus endocrine therapy in breast cancer.
    Alessandroni M; Silber JH
    Lancet; 1984 Oct; 2(8408):922-3. PubMed ID: 6148637
    [No Abstract]   [Full Text] [Related]  

  • 30. Adjuvant therapy in breast cancer.
    Dorr A
    Curr Opin Oncol; 1990 Dec; 2(6):1049-52. PubMed ID: 2099836
    [No Abstract]   [Full Text] [Related]  

  • 31. Multiple trials of adjuvant chemohormonal therapy in the treatment of breast cancer: preliminary results--the ECOG experience.
    Carbone PP
    Breast Cancer Res Treat; 1983; 3 Suppl():S35-8. PubMed ID: 6367858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolving concepts in the systemic adjuvant treatment of breast cancer.
    Bonadonna G
    Cancer Res; 1992 Apr; 52(8):2127-37. PubMed ID: 1559216
    [No Abstract]   [Full Text] [Related]  

  • 33. Endocrine function in premenopausal and postmenopausal advanced breast cancer patients treated with CMF or tamoxifen.
    Bhatavdekar JM; Shah NG; Patel DD; Karelia NH; Trivedi SN; Vora HH; Ghosh N; Giri DD; Balar DB
    Neoplasma; 1992; 39(2):123-7. PubMed ID: 1528310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant systemic therapy for operable breast cancer.
    Stewart HJ
    Br Med Bull; 1991 Apr; 47(2):343-56. PubMed ID: 1933218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant CMF chemotherapy in operable breast cancer: ten years later.
    Bonadonna G; Rossi A; Valagussa P
    Lancet; 1985 Apr; 1(8435):976-7. PubMed ID: 2859425
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of adjuvant tamoxifen and CMF on endocrine function of patients with operable breast cancer.
    Bianco AR; De Placido S; Pagliarulo C; Fasano S; D'Istria M; De Sio L; Ricciardi I; Delrio G
    Chemioterapia; 1985 Jun; 4(3):252-5. PubMed ID: 3839720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The EBCTCG overview of adjuvant therapy of breast cancer. What are the implications for future studies? Early Breast Cancer Trialists' Collaborative Group.
    Gray R; Clarke M; Collins R; Peto R
    Ann N Y Acad Sci; 1993 Nov; 698():339-48. PubMed ID: 8279773
    [No Abstract]   [Full Text] [Related]  

  • 38. Adjuvant CMF chemotherapy in operable breast cancer: ten years later.
    Bonadonna G; Rossi A; Valagussa P
    World J Surg; 1985 Oct; 9(5):707-13. PubMed ID: 3840626
    [No Abstract]   [Full Text] [Related]  

  • 39. Adjuvant therapy for early breast cancer.
    Costa SD; Bischoff J
    N Engl J Med; 2007 Mar; 356(12):1268-9. PubMed ID: 17377168
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.
    Bertelsen L; Bernstein L; Olsen JH; Mellemkjaer L; Haile RW; Lynch CF; Malone KE; Anton-Culver H; Christensen J; Langholz B; Thomas DC; Begg CB; Capanu M; Ejlertsen B; Stovall M; Boice JD; Shore RE; ; Bernstein JL
    J Natl Cancer Inst; 2008 Jan; 100(1):32-40. PubMed ID: 18159070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.